<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02488564</url>
  </required_header>
  <id_info>
    <org_study_id>IRST174.09</org_study_id>
    <nct_id>NCT02488564</nct_id>
  </id_info>
  <brief_title>A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer</brief_title>
  <acronym>met-HEReMYTA</acronym>
  <official_title>Clinical and Translational Phase II Study of Liposomal Doxorubicin Plus Docetaxel and Trastuzumab With Metformin as Primary Systemic Therapy for Operable and Locally Advanced Recombinant Human ErbB-2 (HER2) Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a multicenter, open-label, two stage phase II trial, to assess activity, safety and
      potential early predictors of response in neoadjuvant setting. Patients with operable breast
      cancer (T1c and cytologically N1-2, or cT2-3, N0-N2, M0) or locally advanced breast cancer
      (T4a-d, N0-N2, M0) with overexpression or amplification of HER2 (AJCC 7th edition 2010) are
      included in the study.

      The primary objective is to evaluate the pathological complete response rate (pCR).

      The secondary objectives are:

        -  to evaluate the clinical response rate (RR).

        -  to evaluate the feasibility and systemic tolerance, with particular attention to cardiac
           toxicity.

        -  to evaluate the conservative surgery rate.

      Total duration of the trial is 36 months; planned treatment are 6 cycles of chemotherapy. At
      every cycle (every 21 days) will be administered:

      Day 1: Liposome-encapsulated doxorubicin, 50 mg/m2 IV 1 hour infusion; Day 2 and 9:
      Docetaxel, 30 mg/m2 IV 1 hour infusion; Day 2, 9 and 16: Trastuzumab 4 mg/kg for the first
      infusion loading dose, then 2 mg/kg/week for subsequent injections. Day -13 to 0: Metformin
      is administered as single agent. From day -13 to day -11, Metformin 1000 mg will be
      administered once a day; from day -10 Metformin 1000 mg will be administered twice a day
      continuously until end of the study treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, open-label phase II trial to assess activity of this chemotherapy scheme
      evaluated by pathologic complete response rate (pCR).

      Planned treatment are 6 cycles of chemotherapy.

      At every cycle (every 21 days) will be administered:

      Day 1: Liposome-encapsulated doxorubicin, 50 mg/m2 IV 1 hour infusion; Day 2 and 9:
      Docetaxel, 30 mg/m2 IV 1 hour infusion; Day 2, 9 and 16: Trastuzumab 4 mg/kg for the first
      infusion loading dose, then 2 mg/kg/week for subsequent injections Day -13 to 0: Metformin is
      administered as single agent. From day -13 to day -11, Metformin 1000 mg will be administered
      once a day; from day -10 Metformin 1000 mg will be administered twice a day continuously
      until end of the study treatment.

      Total duration of the trial: 36 months Enrollment period: 24 months Treatment: maximum of 6
      cycles (5 months) per patient Follow-up for recurrence: every six months for 5 years, than
      once a year until 10 years after surgery.It's necessary to recruit 46 patients for clinical
      objectives evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response rate(pCR)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Complete pathologic response will be defined as no invasive residuals in breast and axillary nodes. In situ tumor residuals are considered as complete response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical response rate (RR)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>The clinical response rate (RR) will be including Pathological Complete Response, Clinical Complete Response and Clinical Partial Response (Response Evaluation Criteria in Solid Tumors (RECIST) criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of toxicity</measure>
    <time_frame>up to 36 months</time_frame>
    <description>All patients will be evaluable for toxicity from the time of their first treatment with Metformine. The toxicity will be recorded according to the CTC-AE, version 4.0 in the safety population until Follow-up is completed (36 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>conservative surgery rate</measure>
    <time_frame>up to 36 months</time_frame>
    <description>evaluation of the number of patients who underwent conservative surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>HER-2 Positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Liposomal doxorubicin +Docetaxel+Trastuzumab+Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Liposome-encapsulated doxorubicin, 50 mg/m2 IV 1 hour infusion; Day 2 and 9: Docetaxel, 30 mg/m2 IV 1 hour infusion; Day 2, 9 and 16: Trastuzumab 4 mg/kg for the first infusion loading dose, then 2 mg/kg/week for subsequent injections.
Day -13 to 0: Metformin is administered as single agent. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10 Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal doxorubicin</intervention_name>
    <description>50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required</description>
    <arm_group_label>Liposomal doxorubicin +Docetaxel+Trastuzumab+Metformin</arm_group_label>
    <other_name>Myocet®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>30 mg/m2 by intravenous infusion over a period of 1 hour on day 2 and 9, every 3 week.They will be given for 6 cycles.</description>
    <arm_group_label>Liposomal doxorubicin +Docetaxel+Trastuzumab+Metformin</arm_group_label>
    <other_name>taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>4 mg/kg for the first administration (day 2 cycle 1) and 2 mg/kg for subsequent administrations. Trastuzumab will be given weekly for the duration of chemotherapy (day 2, 9, 16), then will be administered at the dose of 6 mg/Kg every 3 weeks until completion of 52 weeks of treatment.</description>
    <arm_group_label>Liposomal doxorubicin +Docetaxel+Trastuzumab+Metformin</arm_group_label>
    <other_name>herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>It is administered as single agent from day -13 to 0. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10, Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.</description>
    <arm_group_label>Liposomal doxorubicin +Docetaxel+Trastuzumab+Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically confirmed breast cancer

          -  HER2 overexpressing cancer

          -  Patients with operable breast cancer (T1c and cytologically N1-2, or cT2-3, N0-N2, M0)
             or locally advanced breast cancer (T4a-d, N0-N2, M0) (AJCC 7th edition 2010).

          -  No prior therapy for breast cancer

          -  Both sexes, age ≥ 18 years and &lt; 75 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Life expectancy &gt; 3 months

          -  Neutrophil count ≥ 2 x 109/ L, leukocytes count ≥ 3 x 109/ L and platelet count ≥ 100
             x 109/ L

          -  Total bilirubin ≤ 1 upper-normal limits (UNL) of the Institutional normal values and
             alanine aminotransferase (ASAT (GOT) and/or alanine aminotransferase ALAT (GPT) ≤ 2.5
             UNL, alkaline phosphatase ≤ 5 UNL. Patients with ASAT and/or ALAT &gt; 1.5 UNL and
             alkaline phosphatase &gt; 2.5 UNL aren't eligible for the trial.

          -  Creatinine ≤ 1.5 mg/dL

          -  Left ventricular ejection fraction (LVEF) ≥ 50% (evaluated by echocardiogram or
             multiple gated acquisition scan (MUGA) scan -only one method must be employed for each
             patient)

          -  Written informed consent

          -  Homa Index calculated using the Matthews'formula

        EXCLUSION CRITERIA:

          -  Prior chemotherapy or radiotherapy for breast cancer.

          -  History of prior malignancy in the last 10 years (other than non-melanoma skin cancer
             or excised cervical carcinoma in situ).

          -  Other serious illness or medical condition

          -  Congestive heart failure or angina pectoris even if medically controlled. Previous
             history of myocardial infarction, uncontrolled high risk hypertension or arrhythmia

          -  History of significant neurologic or psychiatric disorders including dementia or
             seizures

          -  Active infection

          -  Concurrent treatment with other experimental drugs.

          -  Participation in another clinical trial with any investigational agents within 30 days
             prior to study screening.

          -  Geographic inaccessibility to treatment and followup

          -  Pregnant and lactating women

          -  Diabetes-insulin dependant and non-insulin dependant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Fedeli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRST IRCCS, Meldola-Cesena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oriana Nanni, PhD</last_name>
    <phone>+390543739266</phone>
    <email>oriana.nanni@irst.emr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRST Oncologia medica</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Fedeli, MD</last_name>
      <phone>0547 352975</phone>
      <email>anna.fedeli@irst.emr.it</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Rocca</last_name>
      <email>andrea.rocca@irst.emr.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica AOU Ferrara</name>
      <address>
        <city>Ferrara</city>
        <state>FE</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Frassoldati</last_name>
      <email>a.frassoldati@ospfe.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica, Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Cortesi, MD</last_name>
      <email>hbc@unimore.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica Ospedale Guglielmo da Saliceto</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Cavanna</last_name>
      <email>l.cavanna@ausl.pc.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncologia , IRCCS azienda ospedaliera S.Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giancarlo Bisagni, MD</last_name>
      <email>bisagni.giancarlo@asmn.re.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O Oncologia AUSLdella Romagna</name>
      <address>
        <city>Rimini</city>
        <state>RN</state>
        <zip>47923</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Gianni, MD</last_name>
      <phone>0541 705413</phone>
      <email>lgianni@auslrn.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Day Hospital Oncologico, Ospedale Guastalla</name>
      <address>
        <city>Guastalla</city>
        <zip>42016</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Scaltriti, MD</last_name>
      <email>laura.scaltriti@ausl.re.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica AUSL Imola</name>
      <address>
        <city>Imola</city>
        <zip>40133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Maestri, MD</last_name>
      <email>a.maestri@ausl.imola.bo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica AOU Parma</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Musolino, MD</last_name>
      <email>amusolino@ao.pr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER-2 Positive Breast Cancer</keyword>
  <keyword>operable breast cancer</keyword>
  <keyword>locally advanced breast cancer</keyword>
  <keyword>no prior therapy</keyword>
  <keyword>pCR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

